📰 Suboptimal Response News

Suboptimal Response News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Suboptimal Response. Real-time updates on events, politics, business and more.

Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting

November 2, 2023

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature...

United Kingdom United States San Diego Ponatinib Iclusig Pabloj Cagnoni Incyte Corporation

Source: marketscreener.com

Applying CATT Study Results in Real World

July 13, 2023

Experts discuss the comparison of age-related macular degeneration treatments trials (CATT) and how today’s retina specialists can apply the results in their daily practice.

Anti Vegf Age Related Macular Degeneration Macular Degeneration Diabetic Macular Edema Suboptimal Response

Source: hcplive.com

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

May 25, 2023

Incyte today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held... | May 25, 2023

United Kingdom United States Tafasitamab Monjuvi Ponatinib Iclusig Steven Stein Macrogenics Inc

Source: marketscreener.com

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress Seite 1

May 25, 2023

25.05.2023 - Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago, and at the ... Seite 1

Activin Receptor Like Kinase Hematologic Malignancies Myelodysplastic Syndromes Open Label Study Add On Therapy Suboptimal Response

Source: wallstreet-online.de

Data from Across Incyte's Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

May 25, 2023

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual

United Kingdom United States Tafasitamab Monjuvi Gewinn Nur Catalina Loveman Ponatinib Iclusig

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion To Participate in Upcoming Scientific and Investor Conferences

September 12, 2022

Investegate announcements from Oxurion NV, Oxurion To Participate in Upcoming Scientific and Investor Conferences

United States Region Flamande Tom Graney Rahul Khurana American Academy Of Ophthalmology Oxurion To Participate

Source: investegate.co.uk

AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients

June 10, 2022

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with...

Mohamed Zaki Francesco Passamonti European Hematology Association Drug Administration Congress Abstract Exchange Commission

Source: prnewswire.com

AbbVie Presents Positive Investigational Navitoclax Combination Data in Phase 2 REFINE Study Suggesting Anti-Fibrosis Activity for Patients with Myelofibrosis

April 12, 2022

-          Navitoclax is being studied in myelofibrosis, a rare, difficult-to-treat blood cancer -          Results are from an exploratory analys...

United States Mohamed Zaki Jacquelines Garcia Drug Administration Harvard Medical School Exchange Commission

Source: businessinsider.com

Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

March 25, 2022

Maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in... | March 25, 2022

United States South Korea Nathalie Meetz Levi Garraway Loren Kalm Impact Of Administration Ocrelizumab

Source: marketscreener.com

F. Hoffmann-La Roche Ltd: Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

March 25, 2022

First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue

United States South Korea Nathalie Meetz Levi Garraway Karl Mahler Sabine Borngr

Source: finanznachrichten.de

1 2 3 Next →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Suboptimal Response News Today

Stay Updated with Latest News

Explore More Categories